Why I feel buying the AstraZeneca share price could destroy your retirement riches

Roland Head explains why he’s avoiding AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Buying shares in bad businesses may be the most obvious way to lose money in the stock market.

But there’s another way of losing money that’s almost as dangerous and is often overlooked. I’m talking about valuation. Paying too much for a stock can leave you sitting on a loss for years, while the wider market steams ahead.

The two companies I’m looking at today are good businesses, but they look too expensive to me.

Should you invest £1,000 in NatWest Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if NatWest Group made the list?

See the 6 stocks

Pharma buzz

FTSE 100 pharmaceutical firm AstraZeneca (LSE: AZN) may seem an unlikely choice for this article. Surely this company is conservatively valued, produces reliable profits and pays a generous dividend?

Unfortunately, this isn’t the case. AZN shares have risen by 47% over the last five years to an all-time high of more than £63, despite falling profits and rising debt.

This has left the group trading on 22.2 times 2019 forecast adjusted earnings, with a dividend yield of 3.5% — well below the FTSE 100 average of 4.3%.

In my view, this valuation is pricing in a lot of future progress. I’m also concerned that the company’s preferred measure of adjusted earnings may be flattering its performance, something my colleague G A Chester covered recently in more detail.

Worse than it looks?

Over the last four years, AstraZeneca’s net debt has risen from $7.8bn to $16.3bn. I believe one reason for this is the maintenance of the group’s $2.80 per share dividend.

You see, the company has paid out about $14bn in cash distributions to shareholders since 2015, but has only reported shareholder profits of $11.5bn.

These numbers tell me that Astra is relying heavily on borrowed cash to fund investments in new medicines, while paying out all of its profits (and more) to shareholders.

The situation reached a new low in March, when Astra decided to raise $3.5bn from shareholders just days after paying a dividend of $2.4bn. This seems ludicrous to me — if cash really is that tight, the dividend should be cut.

My verdict: AstraZeneca has an exciting pipeline of new products, but I think the price is far too high, given the group’s weak cash generation and steep valuation. I’d wait for a better opportunity to buy.

Down 13% as spending climbs

My next stock also operates in the pharmaceutical sector, producing antibodies for research labs. Shares in Abcam (LSE: ABC) have risen from about 140p to 1,221p over the last 10 years, valuing this business at over £2.5bn.

However, the stock is down by more than 14% at the time of writing. Today’s fall came after the company announced plans to increase spending on expansion and said its chief financial officer had resigned.

Slowdown?

I should explain that Abcam has delivered high profit margins and strong growth for some years. Profits doubled between 2013 and 2018, for example.

However, earnings per share for the year that ended on 30 June are expected to be broadly unchanged from the previous year. Looking ahead, analysts expect modest earnings growth of 7% for the current year.

With spending rising, it’s not clear to me whether Abcam will be able to maintain its historic operating profit margin of nearly 30%. This risk — plus slower growth — suggests to me that the stock’s forecast price/earnings ratio of 35 is rather high.

As with AstraZeneca, I think this is a good business, but in my view it’s too expensive at the moment.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Abcam and AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Retirement Articles

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Smart investors are using a SIPP to become retirement millionaires! Here’s how to aim high

Investing in a SIPP can supercharge retirement savings and even lead to a million-pound nest egg by sparing just £500…

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Investing £500 a month in a SIPP for the last 10 years could have beaten the State Pension by…

Even with a 10-year time horizon, consistent SIPP investing can provide far better retirement income than the State Pension. Zaven…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

£50K in a SIPP? Here’s how to try and turn it into £250K!

Christopher Ruane explains how a fairly modest annual return could help an investor increase the value of their SIPP fivefold.

Read more »

Wall Street sign in New York City
Investing Articles

Here’s how stock market volatility could help someone retire years early

Is stock market volatility necessarily a bad thing? This writer spies potential opportunity in market turbulence for the long-term investor.

Read more »

Senior woman potting plant in garden at home
Investing Articles

Here’s how a Stocks & Shares ISA investor could target a £27k passive income!

Looking for ways to build a winning Stocks and Shares ISA? Buying FTSE 100, FTSE 250 and S&P 500 shares…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

£20k to spare? Here’s how investors could use that to kickstart a £45k+ passive income

Looking for ways to make a jumbo passive income? Consider investing in this fund that I think, over time,could create…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

£500 to invest in an ISA each month? Here’s how to target a potential £60k+ second income!

A regular monthly investment in a Stocks and Shares ISA could build a huge passive income in retirement. Let me…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Here’s how much a 28-year-old investor could have on retirement by putting £80 a week into a SIPP

Starting younger can have advantages when building up a SIPP. Christopher Ruane runs a slide rule over what value £80…

Read more »